



5-YEAR-OLD BOY WITH PROGRESSIVE PROXIMAL WEAKNESS AND HYPOTONIA

Samantha Weaver, MSN, PNP-AC¹, Carrie Mohila, MD, PhD² and Michael A. Lopez, MD, PhD¹

¹Division of Pediatric Neurology, Department of Pediatrics; University of Alabama at Birmingham | Children's of Alabama ²Department of Pathology & Immunology, Baylor College of Medicine | Texas Children's Hospital

CASE PRESENTATION

5 year-old Hispanic boy presented with:

- 4 months of progressive leg pain, falls, head and leg weakness
- Requiring support to walk up stairs
- Would push on his legs to rise from the floor
- Requiring help to raise his head from chest
- No issues with bowel, bladder, breathing, or appetite

Pertinent history:

- Limited febrile mononucleosis 5 months prior
- Normal birth history and milestones
- Family history remarkable for 3 healthy siblings and 1 maternal cousin who died at age 6 years who could not move well and required total care

EXAM FINDINGS

General: Short stature (1-2nd%ile)

Cranial nerves: Normal

Bulk: Muscle wasting over torso/upper scapula

Tone: Head and trunk hypotonia

Strength: Proximal pattern upper and lower extremity weakness

- weak shoulder shrug
- hip flexors 4-/5

hamstrings 4/5

dorsiflexion 4-/5

quads/

- neck flexion/extension 3/5
- deltoids 3/5
- biceps/triceps 4+/5
- hand grip 5/5

plantar flexion 4/5 DTR: 1+ Reflexes throughout

Gait: Lordotic, waddling, + Gower's sign


DIFFERENTIAL DIAGNOSIS

- Neuronopathies: SMA, juvenile ALS
- Neuropathies: AIDP, CIDP,
- NMJ: Myasthenia (Genetic, immune)
- Myopathies: Dystrophic, congenital, mitochondrial, metabolic (Pompe)

NCS/EMG STUDY

R Median - (Antidro Wrist R Ulnar - Digit N Wrist R Sural - Ankle Calf L Sural - Ankle Calf Motor Nerve / Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head Pop fossa	V (Antidromic) (Calf) (Calf) Muscle	Dig II) Dig V Ankle Ankle Latency	ms 1.56 1.30 1.98	2.14 2.19 2.50	μV 87. 37.	0 W	rist - Dig II rist - Dig V	cm m	n/s r 51.5 41.1	m/s 70.4 69.1
Wrist R Ulnar - Digit V Wrist R Sural - Ankle Calf L Sural - Ankle Calf Motor Nerve / Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head	V (Antidromic) (Calf) (Calf) Muscle) Dig V Ankle Ankle	1.30 1.98	2.19	37.	0 W				
Wrist R Sural - Ankle Calf L Sural - Ankle Calf Motor Nerve / Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head	(Calf) (Calf) Muscle	Dig V Ankle Ankle	1.98				rist - Dig V	9	41.1	69.1
R Sural - Ankle Calf L Sural - Ankle Calf Motor Nerve / Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head	(Calf) Muscle	Ankle Ankle	1.98				rist - Dig V	9	41.1	69.1
Calf L Sural - Ankle Calf Motor Nerve / Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head	(Calf) Muscle	Ankle		2.50	33.					
L Sural - Ankle Calf Motor Nerve / Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head	Muscle	Ankle		2.50	33.					
Calf Motor Nerve / Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head	Muscle		2 08			.9 C	Calf - Ankle	12	48.0	60.
Motor Nerve / Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head			2 08							
Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head		Latency	2.00	2.60	30.	.1 C	Calf - Ankle	12	46.1	57.
Sites R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head		Latency								
R Median - APB Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head			Amplitude	Segments	Dis	tance	Lat Diff	Velocity	Temp	D.
Wrist Elbow Upper arm R Peroneal - EDB Ankle Fib head		ms	mV			cm	ms	m/s	°C	
Upper arm R Peroneal - EDB Ankle Fib head	APB	2.45	7.0	Wrist - A	РВ	7				34
R Peroneal - EDB Ankle Fib head	APB	4.38	7.6	6 Elbow - Wi	rist	10	1.93	52		34
Ankle Fib head	АРВ	5.63	6.5	5 Upper arı Elb		7.5	1.25	60		
Fib head										
	EDB	2.55	6.2	2 Ankle - E	DB	6				
Pop fossa	EDB	5.21	6.0) Fib hea An		16	2.66	60		
	EDB	6.04	5.3	•	Fib ead	6	0.83	72		
Anatomy / Train	Rate	Ampl.	Ampl 4-1	Fac Ampl	А	rea	Area 4-1	Fac Area	Time	
R Ulnar - ADM	Hz	mV	%	%	m'	Vms	%	%		
Baseline	3	6.0	-0.7		00	15.6	2.5			00:0
1 min after Baseline	3	6.0	-1	. 95	0.6	15.4	1.4	98.7	U:0	01:0
Exercise	50	6.1	-26	1	01	15.7	-145	101	0:0	02:3
mmediate	3	6.1	-0.4		01	15.7	1.5	101	0:0	02:5
after Exercise			0.0		0.4	45.0	1.0	401		02.1
30 secs post exercise	3	6.1	-0.3	1	01	15.8	1.8	101	U:0	03:1
4 min post	3	6.0	-0.1	. 99	0.5	15.7	2.7	100	0:0	06:4
exercise										
R Accessory (spin		2.1	4.0		00	24.5	4.3	100		00.0
Baseline 1 min after	3	3.1 3.1	1.2 0.9		00	21.5 21.5	1.2 2.9			00:0 01:0
baseline	3	5.1	0.3	93		21.3	2.3	100	0.0	51.0
Median - Digit II (Antidromi	• • • • • • • • • • • • • • • • • • • •	C R Ulnar - Digit V (Antidrom		SNC R Sural - Ankle (Ca		* *	NC L Sural - Ankle (Calf)	· · · · · · · · · · · · · · · · · · ·	MNC R Median - A	APB
	.1ms10μV		.1ms10μV		1ms			1ms . 2mV .		· ·

MUSCLE BIOPSY FINDINGS



basophilic myofibers, B - Oil red O shows increased lipid deposits and fiber size variation, C - Trichrome shows ragged red fibers, D - COX shows absent and deficient fibers, and E - SDH shows ragged blue fibers hypermetabolic fibers. Scale bar = 100 um.

IMAGING, LAB, & MOLECULAR RESULTS

- Labs: Creatine Kinase = **511 U/L** (30-200), Creactive protein= 0.79 (0-0.50), Lactic Acid 2.1 (0.5-2.2), CSF studies/cultures normal and CSF protein 15.3 (15-40).
- Echocardiogram/EKG, MRI brain/spine unremarkable.
- Genetics (Blood): Invitae Comprehensive Neuromuscular Disorders panel: VUS within RYR. gene. Juvenile ALS panel: negative.
- Genetics (Muscle): Mitochondrial Respiratory Chain Enzyme: negative. BCM-MitoNGS Comprehensive mtDNA: multiple low-level deletions. BCM-MitomeNGS Panel: Homozygous pathogenic variant c.173A>G (p.N58S) in TK2 gene.

CLINICAL SUMMARY

Presentation: Progressive proximal weakness, diminished reflexes, +Gowers; elevated CK, CRP, normal lactic acid

Muscle Biopsy: Ragged red fibers (Fig 1C), intracellular accumulation of lipids (Fig 1B), stained hypermetabolic fibers (Fig 1E)

Genetics: Multiple low-level mitochondrial deletions suggestive of a primary mitochondrial myopathy Mitochondrial genetics: Homozygous pathogenic variant c.173A>G indicating TK2 mitochondrial Depletion Syndrome

Management:

- Coenzyme Q10 at 10 mg/kg/day
- Gastrostomy tube for weight loss and poor oral intake
- MDA Care: Pulmonary and Rehabilitation services
- Cardiac and audiology evaluation
- Family genetic evaluation and counseling
- Presently receiving compassionate-use nucleotide precursors deoxythymidine (dThd) and deoxycytidine (dCyt) therapy.

DISCUSSION




Figure 3 - Thymine kinase 2 (TK2) mutations. Mutations in the coding and splice-site regions of TK2 (NM_004614.4). Hot-spot exons are marked in red boxes. Protein changes are color-coded based on the clinical phenotype. Protein changes found with more than one clinical phenotype are highlighted with multiple colors. Protein changes found in all of the three forms are noted in black. DNA sequence variants are noted in grey font. Figure from Garone C, et al. J Med Genet 2018.

The TK2 gene encodes thymidine kinase which is involved in production of mitochondrial DNA via recycling of nucleotides. Deficiency leads to an imbalance in pool of DNTs. There are 3 recognized phenotypes with variable onset, severity, and survival: The infantile-onset (<1 year) myopathy: rapid progression with high mortality. Childhood onset (1-12 yo): moderate progression of proximal weakness, positive Gower's sign with high percentage (>50%) of wheelchair and/or ventilatory dependency. Later onset (>12 yo): mild/slow progression

- Our case represents a diagnosis of childhood-onset mitochondrial myopathy / mitochondrial depletion syndrome due to TK2 deficiency
- Consideration of a diagnosis of mitochondrial myopathy in the setting of hypotonia, proximal progressive weakness, and short stature is warranted
- Early evaluation for TK2 deficiency by molecular testing can further direct the treatment options

REFERENCES

1. Hirano M, Emmanuele V, Quinzii CM. Emerging therapies for mitochondrial diseases. Essays Biochem. 2018;62(3):467–81.

2. Garone C, Taylor RW, Nascimento A, et al. Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet 2018;55:515-521.

3. Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, Juanola-Falgarona M, Barca E, Garcia-Diaz B, et al. Deoxycytidine and Deoxythymidine treatment for thymidine kinase 2 deficiency. Ann Neurol. 2017;81(5):641-52.

4. Wang J, El-Hattab AW, Wong LJC. TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form. 2012 Dec 6 [Updated 2018 Jul 26]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.

Special thanks to UAB /COA MDA Clinic, UAB Genetics, UAB Pathology, and UAB Cardiology.